Neoadjuvant SHR-A1811 and SHR-A1701 ± Pertuzumab for Potentially Immunotherapy-Sensitive GC or GEJ Adenocarcinoma

NCT07716111 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Gastric or Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: Trastuzumab Rezatecan and Retlirafusp alfa
DRUG: Trastuzumab Rezatecan and Retlirafusp alfa+Pertuzumab

Sponsor

The First Affiliated Hospital with Nanjing Medical University